Challenges in Clinical Trial Design for T Cell‐Based Cancer Immunotherapy
نویسندگان
چکیده
منابع مشابه
Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design
The rapidly emerging field of immunotherapy and the development of novel immunologic agents that have been approved in melanoma and successfully studied in lung cancer, kidney cancer, and prostate cancer have mandated that there be uniformity in clinical trial analysis beyond conventional survival endpoints and imaging. This includes some measure of determining whether the immunologic target is...
متن کاملImmunotherapy for Breast Cancer Treatment
Breast cancer, as a heterogeneous disease, includes a wide range of pathological and clinical behaviors. Current treatment protocols, including radiotherapy, chemotherapy, and hormone replacement therapy, are mainly associated with poor response and high rate of recurrence. Therefore, more efforts are needed to develop alternative therapies for this type of cancer. Immunotherapy, as a novel str...
متن کاملDesign and development of CAR-T cells for cancer therapy
Introduction: Today, treatment with CAR-T cells is accepted as an effective treatment for blood malignancies. CAR-T cells are autologous T cells that are engineered by gene transfer techniques to express a chimeric antigen receptor (CAR). Despite the promising results and the approval of six CAR-T cell products; these products have not yet been approved for solid tumors. In addition, the high c...
متن کاملChallenges in clinical trial design for recurrent glioblastoma
Glioblastomas are rare tumors but aggressive and often incurable. Since clinical trial enrollment is limited by the relative rarity of the disease, clinical trials should be well designed so that advances are made efficiently. The field has been dominated by smaller Phase II studies since they provide the initial screening of drug efficacy. These studies are prone to issues of selection bias, i...
متن کاملConsiderations on clinical use of T cell immunotherapy for cancer.
The recognition by effector T lymphocytes of novel antigenic targets on tumor cells is the premise of specific, targeted immunotherapy of cancer. With the molecular characterization of peptide epitopes from melanoma antigens and, more recently, broadly expressed tumor antigens, there has been considerable enthusiasm for clinical evaluation of peptide tumor vaccines. Immunologic monitoring of va...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Pharmacology & Therapeutics
سال: 2019
ISSN: 0009-9236,1532-6535
DOI: 10.1002/cpt.1659